Business
InnoCare Releases 2025 Interim Results and Business Highlights
BEIJING, August 19, 2025--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2025 interim results as of 30 June 2025.
About this update from Innocare Pharma Ltd. Class A
[{"type":"text","content":"BEIJING, August 19, 2025--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2025 interim results as of 30 June 2025.","length":227,"tagName":"p"},{"type":"text","content":"Significant Revenue Growth from Orelabrutinib","length":45,"tagName":"p"},{"type":"text","content":"Total Revenue of InnoCare increased by 74.3% year-on-year (YoY) to RMB731.4 million1 for the six months ended 30 June 2025, primarily attributable to the robust sales growth of orelabrutinib and license-out revenue from Prolium. Drug sales increased by 53.5% YoY to RMB641.2 million in the first half of 2025, driven by coverage expansion, an increase in the number of patients treated by orelabrutinib, especially in marginal zone lymphoma, as well as strong commercial execution. Loss for the period decreased by 86.7% to RMB35.6 million for the six months ended 30 June 2025, attributed to revenue growth and improved cost efficiency.","length":637,"tagName":"p"},{"type":"text","content":"Research and development expenses increased by 6.9% YoY to RMB449.7 million for the six months ended 30 June 2025 primarily due to increased investment in advanced technology platforms and a greater number of Phase III clinical trials.","length":235,"tagName":"p"},{"type":"text","content":"Cash and related accounts balances2 stood at approximately RMB7.7 billion as of 30 June 2025. This robust cash position provides flexibility for the Company to expedite clinical development and invest in a competitive pipeline, including ADC programs.","length":251,"tagName":"p"},{"type":"text","content":"Accelerating Innovation, Commercialization and Globalization","length":60,"tagName":"p"},{"type":"text","content":"In the first half of 2025, InnoCare made substantial progress in advancing its pipeline with multiple key milestones achieved: Orelabrutinib received approval for first-line chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), tafasitamab in combination with lenalidomide was approved for adult patients with relapsed or refractory DLBCL (R/R DLBCL), BCL-2 inhibitor Mesutoclax (ICP-248) entered two registrational clinical studies, the NDA for TRK inhibitor Zurletrectinib (ICP-723) was accepted and granted priority review, and the Company’s proprietary antibody-dr...